Disease · MONDO_0007608
Trials34
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
1 to 20 of 34
Download this page as JSON| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03785964 | Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | Phase 3 | 142 | 2024-06-12 | Desmoid Tumor, Aggressive Fibromatosis | NIROGACESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT02066181 | Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis | Phase 3 | 87 | 2019-09-20 | Desmoid Fibromatosis | SORAFENIB TOSYLATE | Its record names the disease | ClinicalTrials.gov |
| NCT01876082 | PAZOPANIB Efficacy and Tolerance in Desmoids Tumors | Phase 2 | 72 | 2021-03-05 | Progressive Desmoids Tumors | PAZOPANIB, VINBLASTINE | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov |
| NCT00068419 | Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor | Phase 2 | 70 | 2013-12-04 | Desmoid Tumor | SULINDAC, TAMOXIFEN | Its record names the disease | ClinicalTrials.gov |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | Phase 1/2 | 34 | 2025-02-17 | Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor, Chordoma, Non Small Cell Lung Cancer, Urothelial Carcinoma, Melanoma, Renal Cell Carcinoma, Squamous Cell Carcinoma, Hepatocellular Carcinoma, Classical Hodgkin Lymphoma, Colorectal Cancer, MTOR Activating Mutation | NIVOLUMAB, SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT02145741 | Weekly Intravenous Administrations of BI 836845 in Japanese Patients With Advanced Solid Tumours | Phase 1 | 21 | 2025-06-19 | Neoplasms | XENTUZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01981551 | Phase II Trial of the Gamma-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors/Aggressive Fibromatosis | Phase 2 | 17 | 2020-02-05 | Desmoid Tumors, Aggressive Fibromatosis | NIROGACESTAT | Its record names the disease | ClinicalTrials.gov |
| NCT01265030 | A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis | Phase 1/2 | 9 | 2023-06-26 | Desmoid Tumor | SIROLIMUS | Its record names the disease | ClinicalTrials.gov |
| NCT03886311 | Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma | Phase 2 | 200 | Sarcoma | NIVOLUMAB, TALIMOGENE LAHERPAREPVEC, TRABECTEDIN | Its record names the disease | ClinicalTrials.gov | |
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | 147 | Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor | TEGAVIVINT | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01292655 | Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors | Phase 1 | 94 | Cancer | OSUGACESTAT | Open Targets' reading, confirmed by NLM's indexing of its papers | ClinicalTrials.gov | |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | Phase 1 | 80 | Cancer, Melanoma, Breast Cancer, Head and Neck Cancer, Lymphoma, Triple-Negative Breast Cancer | IPILIMUMAB, PEMBROLIZUMAB, RUXOTEMITIDE | Its record names the disease | ClinicalTrials.gov | |
| NCT00002595 | Toremifene in Treating Patients With Desmoid Tumors | Phase 2 | 72 | Desmoid Tumor | TOREMIFENE | Its record names the disease | ClinicalTrials.gov | |
| NCT05561036 | A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor | Phase 3 | 72 | Desmoid Tumor | DOXORUBICIN | Its record names the disease | ClinicalTrials.gov | |
| NCT03275818 | Trial of Nab-paclitaxel in Patients With Desmoid Tumors and Multiply Relapsed/Refractory Desmoplastic Small Round Cell Tumors and Ewing Sarcoma | Phase 2 | 69 | Tumor, Desmoplastic Small Round Cell, Adult, Tumor, Desmoplastic Small Round Cell, Childhood, Sarcoma, Ewing, Sarcoma, Desmoid | PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT07176689 | Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) | Phase 4 | 50 | Desmoid Tumor, Aggressive Fibromatosis | NIROGACESTAT | Its record names the disease | ClinicalTrials.gov | |
| NCT00287846 | Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis | Phase 1/2 | 40 | Desmoid Tumor | IMATINIB, IMATINIB MESYLATE | Its record names the disease | ClinicalTrials.gov | |
| NCT01273168 | Endoxifen in Adults With Hormone Receptor Positive Solid Tumors | Phase 1 | 40 | Hormone Receptor-Positive Breast, Gynecologic, Desmoid, Hormone Receptor-Positive Neoplasms | ENDOXIFEN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05879146 | Evaluation of the Response and Non-response of Nirogacestat in Desmoid Tumors- Clinical Study | Phase 2 | 40 | Tumor | NIROGACESTAT | Its record names the disease | ClinicalTrials.gov | |
| NCT00928525 | Imatinib in Patients With Desmoid Tumor and Chondrosarcoma | Phase 2 | 35 | Advanced Desmoid Tumor, Advanced Chondrosarcoma | IMATINIB | Its record names the disease | ClinicalTrials.gov |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007608/trials